Pediatric Non-Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
16
3
2021
medline:
15
10
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in both adults and children. Along with obesity and metabolic syndrome, genetic predisposition influences the progression of NAFLD. Here, we investigated the effect of lifespan/healthspan-related single nucleotide polymorphisms (SNPs) on metabolically associated fatty liver disease in children. We evaluated the impact of 10 SNPs involved in both human liver/metabolic diseases and healthspan (interleukin-6 [IL-6] rs1800795, antisense non coding RNA in the INK4 locus (ANRIL) rs1556516, SH2B3/ATXN2 rs7137828, FURIN rs17514846, TP53 rs1042522, APOC3 rs2542052, KL rs9536314, KL rs9527025, SIRT6 rs107251, FOXO3 rs2802292) on NAFLD-related metabolic and liver features in 177 pediatric patients with biopsy-proven NAFLD, by comparing them to 146 healthy controls. We then applied a multidimensional reduction (MDR) case-control analysis of SNP-SNP interactions, to identify the joint effect of analyzed SNPs in predicting NAFLD and associated features. Discrete SNPs were significantly associated with individual metabolic NAFLD features, but none of them significantly associated with NAFLD diagnosis. By testing potential synergies using the MDR approach, the best combination to diagnose NAFLD (P = 0.0011) resulted in the one encompassing IL-6 rs1800795 and ANRIL rs1556516. Consistently, the risk combinations suggested by SNP-SNP analysis strongly associated with a higher level of fasting plasma blood glucose level (P = 0.024). In conclusion, here we demonstrated a synergic interaction between IL-6 rs1800795 and ANRIL rs1556516 in the diagnosis of NAFLD, and NAFLD-associated hyperglycemia in children. Larger studies are required to confirm our findings and to elucidate mechanisms by which the genetic interaction between these two genes influences healthspan in pediatric NAFLD.
Identifiants
pubmed: 33720087
doi: 10.1097/MPG.0000000000003123
pii: 00005176-202108000-00008
doi:
Substances chimiques
SIRT6 protein, human
EC 3.5.1.-
Sirtuins
EC 3.5.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-168Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158:1999.e1–2014.e1.
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol 2019; 70:531–544.
Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147:754–764.
Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci 2016; 61:1226–1233.
Nobili V, Alisi A, Newton KP, et al. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology 2016; 150:1798–1810.
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461–1465.
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46:352–356.
Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52:1274–1280.
Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61:506–514.
Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013; 58:1218–1229.
Dongiovanni P, Crudele A, Panera N, et al. beta-Klotho gene variation is associated with liver damage in children with NAFLD. J Hepatol 2020; 72:411–419.
Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016; 65:1026–1037.
Bomba L, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common disease. Genome Biol 2017; 18:77doi: 10.1186/s13059-017-1212-4.
doi: 10.1186/s13059-017-1212-4
Melzer D, Pilling LC, Ferrucci L. The genetics of human ageing. Nat Rev Genet 2020; 21:88–101.
Franceschi C, Garagnani P, Olivieri F, et al. The contextualized genetics of human longevity: JACC focus seminar. J Am Coll Cardiol 2020; 75:968–979.
Longo VD, Antebi A, Bartke A, et al. Interventions to slow aging in humans: are we ready? Aging Cell 2015; 14:497–510.
Ruby JG, Wright KM, Rand KA, et al. Estimates of the heritability of human longevity are substantially inflated due to assortative mating. Genetics 2018; 210:1109–1124.
Longo VD. Programmed longevity, youthspan, and juventology. Aging Cell 2019; 18:e12843doi: 10.1111/acel.12843.
doi: 10.1111/acel.12843
Huang Y, Xiang B, Liu Y, et al. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett 2018; 437:56–66.
Ueyama C, Horibe H, Yamase Y, et al. Association of FURIN and ZPR1 polymorphisms with metabolic syndrome. Biomed Rep 2015; 3:641–647.
Di Pietro F, Dato S, Carpi FM, et al. TP53∗P72 allele influences negatively female life expectancy in a population of central Italy: cross-sectional study and genetic-demographic approach analysis. J Gerontol A Biol Sci Med Sci 2013; 68:539–545.
Gross S, Immel UD, Klintschar M, et al. Germline genetics of the p53 pathway affect longevity in a gender specific manner. Curr Aging Sci 2014; 7:91–100.
Rebbani K, Marchio A, Ezzikouri S, et al. TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol Cancer 2015; 14:74doi: 10.1186/s12943-015-0340-2.
doi: 10.1186/s12943-015-0340-2
Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006; 4:e113doi: 10.1371/journal.pbio.0040113.
doi: 10.1371/journal.pbio.0040113
Xie B, Zhou J, Yuan L, et al. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 2013; 44:795–801.
Poh W, Wong W, Ong H, et al. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 2012; 11:14doi: 10.1186/1476-4598-11-14.
doi: 10.1186/1476-4598-11-14
TenNapel MJ, Lynch CF, Burns TL, et al. SIRT6 minor allele genotype is associated with >5-year decrease in lifespan in an aged cohort. PLoS One 2014; 9:e115616.
Banasik K, Ribel-Madsen R, Gjesing AP, et al. The FOXO3A rs2802292 G-allele associates with improved peripheral and hepatic insulin sensitivity and increased skeletal muscle-FOXO3A mRNA expression in twins. J Clin Endocrinol Metab 2011; 96:E119–E124.
Hurme M, Lehtimaki T, Jylha M, et al. Interleukin-6-174G/C polymorphism and longevity: a follow-up study. Mech Ageing Dev 2005; 126:417–418.
Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: a meta-analysis. Medicine (Baltimore) 2019; 98:e18408.
Kong Y, Hsieh CH, Alonso LC. ANRIL: a lncRNA at the CDKN2A/B locus with roles in cancer and metabolic disease. Front Endocrinol (Lausanne) 2018; 9:405.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313–1321.
Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138–147.
Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004; 4:795–803.
Miao L, Yin RX, Pan SL, et al. BCL3-PVRL2-TOMM40 SNPs, gene–gene and gene–environment interactions on dyslipidemia. Sci Rep 2018; 8:6189doi: 10.1038/s41598-018-24432-w.
doi: 10.1038/s41598-018-24432-w
Chen L, Lin Z, Jiang M, et al. Genetic variants in the SAMM50 gene create susceptibility to nonalcoholic fatty liver disease in a Chinese Han population. Hepat Mon 2015; 15:e31076doi: 10.5812/hepatmon.31076.
doi: 10.5812/hepatmon.31076
Dato S, Soerensen M, De Rango F, et al. The genetic component of human longevity: new insights from the analysis of pathway-based SNP–SNP interactions. Aging Cell 2018; 17:e12755doi: 10.1111/acel.12755.
doi: 10.1111/acel.12755
Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018; 68:268–279.
Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet 2015; 24 (R1):R85–R92.
Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18:4081–4088.
Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 2012; 55:661–663.
Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745–E751.
Fernandez-Real JM, Broch M, Vendrell J, et al. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49:517–520.
Zhang B, Wang D, Ji TF, et al. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-kappaB signaling pathway in a rat model. Oncotarget 2017; 8:17347–17359.
Zhou X, Han X, Wittfeldt A, et al. Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-kappaB pathway. RNA Biol 2016; 13:98–108.
Thomas AA, Feng B, Chakrabarti S. ANRIL: a regulator of VEGF in diabetic retinopathy. Invest Ophthalmol Vis Sci 2017; 58:470–480.
Polonsky KS, Sturis J. Bell GI seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334:777–783.
Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893–2898.
Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016; 170:e161971.
Bedogni G, Gastaldelli A, Manco M, et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis 2012; 22:120–126.
Cali AM, De Oliveira AM, Kim H, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009; 49:1896–1903.
Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol 2019; 71:802–810.